

# Chapter 222

## Other Topical Medications

Craig N. Burkhart & Kenneth A. Katz

### REFERENCES

1. Papoiu AD, Yosipovitch G: Topical capsaicin. The fire of a "hot" medicine is reignited. *Expert Opin Pharmacother* 11:1359-1371, 2010
2. Backonja MM et al: NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: A randomized, double-blind, controlled study with an open-label extension. *Pain Med* 11:600-608, 2010
3. Tyring SK: Management of herpes zoster and postherpetic neuralgia. *J Am Acad Dermatol* 57:S136-S142, 2007
4. Kaweski S: Topical anesthetic creams. *Plast Reconstr Surg* 121:2161-2165, 2008
5. Briggs M, Nelson EA: Topical agents or dressings for pain in venous leg ulcers. *Cochrane Database Syst Rev* 4:CD001177, 2010
6. Guay J: Methemoglobinemia related to local anesthetics: A summary of 242 episodes. *Anesth Analg* 108:837-845, 2009
7. Marra DE et al: Systemic toxicity from topically applied lidocaine in conjunction with fractional photothermolysis. *Arch Dermatol* 142:1024-1026, 2006
8. Public Health Advisory: Life-threatening side effects with the use of skin products containing numbing ingredients for cosmetic procedures [Internet]. FDA: Rockville, MD, <http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm054718.htm>, accessed Feb 6, 2007 [cited Jul 8, 2010]
9. FDA Warns Five Firms to Stop Compounding Topical Anesthetic Creams. Rockville, MD, FDA, <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108793.htm>, accessed Dec 5, 2006 [cited Jul 8, 2010]
10. Paghдал KV, Schwartz RA: Topical tar: Back to the future. *J Am Acad Dermatol* 61:294-302, 2009
11. Stoughton RB, DeQuoy P, Walter JF: Crude coal tar plus near ultraviolet light suppresses DNA synthesis in epidermis. *Arch Dermatol* 114:43-45, 1978
12. Alora-Palli MB et al: Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: A controlled comparison with calcipotriene (calcipotriol) cream. *Am J Clin Dermatol* 11:275-283, 2010
13. Brouda I et al: Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis. *Cutis* 85:214-220, 2010
14. Maughan WZ et al: Incidence of skin cancers in patients with atopic dermatitis treated with ocal tar. A 25-year follow-up study. *J Am Acad Dermatol* 3:612-615, 1980
15. Saap L et al: Contact sensitivity in patients with leg ulcerations: A North American study. *Arch Dermatol* 140:1241-1246, 2004
16. Warnecke J, Wendt A: Anti-inflammatory action of pale sulfonated shale oil (ICHTHYOL pale) in UVB erythema test. *Inflamm Res* 47:75-78, 1998
17. Schewe C et al: Inhibitory effects of sulfonated shale oils (ammonium bituminosulphonates, Ichthyols) on enzymes of polyenoic fatty acid metabolism. *Arch Dermatol Res* 286:137-141, 1994
18. Korting HC et al: Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: A multicentre, randomized vehicle-controlled trial. *J Eur Acad Dermatol Venereol* 24(10):1176-1182, 2010
19. Beckert S et al: Efficacy of topical pale sulfonated shale oil in the treatment of venous leg ulcers: A randomized, controlled, multicenter study. *J Vasc Surg* 43:94-100, 2006
20. Schmid MH, Korting HC: Coal tar, pine tar and sulfonated shale oil preparations: Comparative activity, efficacy and safety. *Dermatology* 193:1-5, 1996
21. Balabanova M, Popova L, Tchipeva R: Dyes in dermatology. *Clin Dermatol* 21:2-6, 2003
22. Tsubaki T, Honma Y, Hoshi M: Neurological syndrome associated with clioquinol. *Lancet* 1:696-697, 1971
23. Meade TW: Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis. *Br J Prev Soc Med* 29:157-169, 1975

24. Lio PA, Kaye ET: Topical antibacterial agents. *Infect Dis Clin North Am* 23:945-63, ix, 2009
25. Koning S et al: Efficacy and safety of retapamulin ointment as treatment of impetigo: Randomized double-blind multicentre placebo-controlled trial. *Br J Dermatol* 158:1077-1082, 2008
26. Gollnick H, Layton A: Azelaic acid 15% gel in the treatment of rosacea. *Expert Opin Pharmacother* 9:2699-2706, 2008
27. Sagransky M, Yentzer BA, Feldman SR: Benzoyl peroxide: A review of its current use in the treatment of acne vulgaris. *Expert Opin Pharmacother* 10:2555-2562, 2009
28. Strong M, Johnstone PW: Interventions for treating scabies. *Cochrane Database Syst Rev* 2007:CD000320
29. Burkhart CG, Burkhart CN: Safety and efficacy of pediculicides for head lice. *Expert Opin Drug Saf* 5:169-179, 2006
30. Downs AM et al: Evidence for double resistance to permethrin and malathion in head lice. *Br J Dermatol* 141:508-511, 1999
31. Roos TC et al: Pharmacotherapy of ectoparasitic infections. *Drugs* 61:1067-1088, 2001
32. American Academy of Pediatrics: Pediculosis capitis (head lice). In: *Red Book 2009 Report of the Committee on Infectious Diseases*, edited by LK Pickering. Elk Grove Village, IL, American Academy of Pediatrics, 2009, p. 495
33. Fisher AA: *Contact Dermatitis*, 3rd edition. Philadelphia, Lea & Febiger, 1986
34. Stough D et al: Efficacy and safety of spinosad and permethrin creme rinses for pediculosis capitis (head lice). *Pediatrics* 124(3):e389-e395, 2009
35. Solish N et al: A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: Recommendations of the Canadian Hyperhidrosis Advisory Committee. *Dermatol Surg* 33:908-923, 2007
36. Togel B, Greve B, Raulin C: Current therapeutic strategies for hyperhidrosis: A review. *Eur J Dermatol* 12:219-223, 2002
37. Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: Evolving therapies for a well-established phenomenon. *Mayo Clin Proc* 80:657-666, 2005
38. Kavanagh GM, Shams K: Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis. *J Am Acad Dermatol* 55:S115-S117, 2006
39. Kavanagh GM, Oh C, Shams K: BOTOX delivery by iontophoresis. *Br J Dermatol* 151:1093-1095, 2004
40. Patel T, Ishiuj Y, Yosipovitch G: Menthol: A refreshing look at this ancient compound. *J Am Acad Dermatol* 57:873-878, 2007
41. Patel T, Yosipovitch G: Therapy of pruritus. *Expert Opin Pharmacother* 11:1673-1682, 2010
42. *Code of Federal Regulations* Title 21, Volume 5, Chapter I, Part 347—Skin Protectant Drug Products for Over-the-counter Human Use: Subpart A—Astringent Drug Products, pp. 270-271 [CITE: 21CFR347], revised as of Apr 1, 2002
43. Chou TD et al: Methemoglobinemia secondary to topical silver nitrate therapy—A case report. *Burns* 25:549-552, 1999
44. Rendon M et al: Treatment of melasma. *J Am Acad Dermatol* 54:S272-S281, 2006
45. Grimes PE et al: Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. *J Am Acad Dermatol* 62:962-967, 2010
46. Department of Health and Human Services, Food and Drug Administration: *Skin Bleaching Drug Products for Over-the-Counter Human Use: Proposed Rule*. Federal Register Aug 29, 2006 (Vol. 71, No. 167, pp. 51146-51155), <http://www.fda.gov/ohrms/dockets/98fr/e6-14263.htm>, accessed Jul 8, 2010
47. Levitt J: The safety of hydroquinone: A dermatologist's response to the 2006 Federal Register. *J Am Acad Dermatol* 57:854-872, 2007
48. Favored skin-lightening products may soon vanish. In: *Public Resource Newsletter*. Schaumburg, IL, American Academy of Dermatology, Feb 2007, <http://test.neton-line.com/EMAIL/eNewsletters/Public/0207.html>, accessed Jul 8, 2010
49. Katz KA: Topical tretinoin, lung cancer, and lung-related mortality. *Arch Dermatol* 144:945-946, 2008
50. Schilling LM, Dellavalle RP: Dealing with unanticipated mortality in a large randomized clinical trial of topical tretinoin. *Arch Dermatol* 145:76, 2009
51. Powers W, Jr., Shapiro SS, Heremans A: Tretinoin: An established long-term safety profile. *Arch Dermatol* 145:1063-1064, 2009; author reply 4-5
52. Weinstock MA et al: Topical tretinoin therapy and all-cause mortality. *Arch Dermatol* 145:18-24, 2009
53. Hariharan V et al: Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: Relevance to skin depigmentation. *J Invest Dermatol* 130:211-220, 2010

54. Ganemo A, Virtanen M, Vahlquist A: Improved topical treatment of lamellar ichthyosis: A double-blind study of four different cream formulations. *Br J Dermatol* **141**:1027-1032, 1999
55. Lin AN, Nakatsui T: Salicylic acid revisited. *Int J Dermatol* **37**:335-342, 1998
56. Wohlrab W: The influence of urea on the penetration kinetics of topically applied corticosteroids. *Acta Derm Venereol* **64**:233-238, 1984
57. Rawlings AV et al: Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum lipid levels and stratum corneum barrier function. *Arch Dermatol Res* **288**:383-390, 1996
58. Ashcroft DM et al: Combination regimens of topical calcipotriene in chronic plaque psoriasis: Systematic review of efficacy and tolerability. *Arch Dermatol* **136**:1536-1543, 2000
59. Mason J, Mason AR, Cork MJ: Topical preparations for the treatment of psoriasis: A systematic review. *Br J Dermatol* **146**:351-364, 2002
60. Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. *J Am Acad Dermatol* **59**:455-463, 2008
61. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. *J Am Acad Dermatol* **60**:643-659, 2009
62. Buckley DA, Du Vivier AW. The therapeutic use of topical contact sensitizers in benign dermatoses. *Br J Dermatol* **145**:385-405, 2001
63. Gibbs S, Harvey I: Topical treatments for cutaneous warts. *Cochrane Database Syst Rev* **3**:CD001781, 2006
64. Tatti S et al: Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: A randomized controlled trial. *Obstet Gynecol* **111**:1371-1319, 2008
65. Tatti S et al: Polyphenon E: A new treatment for external anogenital warts. *Br J Dermatol* **162**:176-184, 2010

